Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Mysimba 8 mg/90 mg prolonged-release tablets {equilateral_black_triangle}

Active Ingredient:
bupropion hydrochloride , naltrexone hydrochloride
Company:  
Orexigen Therapeutics Ireland Limited See contact details
ATC code: 
A08AA62
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 31 Oct 2023

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF
Orexigen Therapeutics Ireland Limited
Company image
Address
9-10 Fenian Street, Dublin 2, D02 RX24, Ireland
Medical Information Direct Line
+44 20 3966 0116
Medical Information e-mail
[email protected]
Customer Care direct line
+44 20 3966 0116
Medical Information Fax
+44 203 905 2657